A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype

Background Our laboratory and others reported that the stimulation of specific Toll-like receptors (TLRs) affects the immune modulating responses of human multipotent mesenchymal stromal cells (hMSCs). Toll-like receptors recognize “danger” signals, and their activation leads to profound cellular and systemic responses that mobilize innate and adaptive host immune cells. The danger signals that trigger TLRs are released following most tissue pathologies. Since danger signals recruit immune cells to sites of injury, we reasoned that hMSCs might be recruited in a similar way. Indeed, we found that hMSCs express several TLRs (e.g., TLR3 and TLR4), and that their migration, invasion, and secretion of immune modulating factors is drastically affected by specific TLR-agonist engagement. In particular, we noted diverse consequences on the hMSCs following stimulation of TLR3 when compared to TLR4 by our low-level, short-term TLR-priming protocol. Principal Findings Here we extend our studies on the effect on immune modulation by specific TLR-priming of hMSCs, and based on our findings, propose a new paradigm for hMSCs that takes its cue from the monocyte literature. Specifically, that hMSCs can be polarized by downstream TLR signaling into two homogenously acting phenotypes we classify here as MSC1 and MSC2. This concept came from our observations that TLR4-primed hMSCs, or MSC1, mostly elaborate pro-inflammatory mediators, while TLR3-primed hMSCs, or MSC2, express mostly immunosuppressive ones. Additionally, allogeneic co-cultures of TLR-primed MSCs with peripheral blood mononuclear cells (PBMCs) predictably lead to suppressed T-lymphocyte activation following MSC2 co-culture, and permissive T-lymphocyte activation in co-culture with MSC1. Significance Our study provides an explanation to some of the conflicting reports on the net effect of TLR stimulation and its downstream consequences on the immune modulating properties of stem cells. We further suggest that MSC polarization provides a convenient way to render these heterogeneous preparations of cells more uniform while introducing a new facet to study, as well as provides an important aspect to consider for the improvement of current stem cell-based therapies.

[1]  Sergio Romagnani,et al.  Role for Interferon‐γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells , 2006 .

[2]  Sergio Romagnani,et al.  Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. , 2006, Stem cells.

[3]  L. O’Neill,et al.  New insights into the regulation of TLR signaling , 2006, Journal of leukocyte biology.

[4]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[5]  Hong Shen,et al.  TGF-β1/Smad7 Signaling Stimulates Renal Tubulointerstitial Fibrosis Induced by AAI , 2008 .

[6]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.

[7]  A. Nauta,et al.  Modulation of Immune Responses by Mesenchymal Stem Cells , 2007, Annals of the New York Academy of Sciences.

[8]  Jun Tan,et al.  Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.

[9]  A. Caplan Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. , 1995, Connective tissue research.

[10]  S. Beyth,et al.  Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. , 2007, Experimental hematology.

[11]  E. Lombardo,et al.  Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. , 2009, Tissue engineering. Part A.

[12]  M. Pevsner-Fischer,et al.  Toll-like receptors and their ligands control mesenchymal stem cell functions. , 2007, Blood.

[13]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[14]  U. Lendahl,et al.  Cross-talk between the Notch and TGF-β signaling pathways mediated by interaction of the Notch intracellular domain with Smad3 , 2003, The Journal of cell biology.

[15]  Y. Bae,et al.  Role of Toll‐Like Receptors on Human Adipose‐Derived Stromal Cells , 2006, Stem cells.

[16]  Keystone Symposia Cell- & Tissue-based Therapy , 2004 .

[17]  Stefan W Krause,et al.  Species-specific Regulation of Toll-like Receptor 3 Genes in Men and Mice* , 2003, Journal of Biological Chemistry.

[18]  É. Mezey,et al.  Modulation of bone marrow stromal cell functions in infectious diseases by toll-like receptor ligands , 2009, Journal of Molecular Medicine.

[19]  T. Ottenhoff,et al.  Phenotypic and functional profiling of human proinflammatory type‐1 and anti‐inflammatory type‐2 macrophages in response to microbial antigens and IFN‐γ‐ and CD40L‐mediated costimulation , 2006, Journal of leukocyte biology.

[20]  Mohamed H. Sayegh,et al.  Immunomodulation by Mesenchymal Stem Cells , 2008, Diabetes.

[21]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[22]  B. S. Lee,et al.  Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. , 2001, The Journal of clinical endocrinology and metabolism.

[23]  S. Akira,et al.  Toll-like Receptors and Their Signaling Mechanisms , 2003, Scandinavian journal of infectious diseases.

[24]  G. Hoyle,et al.  Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells. , 2007, Experimental hematology.

[25]  F. Marini,et al.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells , 2009, Proceedings of the National Academy of Sciences.

[26]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[27]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[28]  S. Coffelt,et al.  Leucine Leucine-37 Uses Formyl Peptide Receptor–Like 1 to Activate Signal Transduction Pathways, Stimulate Oncogenic Gene Expression, and Enhance the Invasiveness of Ovarian Cancer Cells , 2009, Molecular Cancer Research.

[29]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[30]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[31]  N. Rouas-Freiss,et al.  Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.

[32]  S. Perez,et al.  Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells , 2006, Stem cells.

[33]  A. Tabilio,et al.  Mesenchymal cells recruit and regulate T regulatory cells. , 2008, Experimental hematology.

[34]  D. Mevorach,et al.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.

[35]  Winfried Brenner,et al.  Assessment of the Tissue Distribution of Transplanted Human Endothelial Progenitor Cells by Radioactive Labeling , 2003, Circulation.

[36]  D. Banerjee,et al.  The therapeutic potential of mesenchymal stem cells , 2007, Expert opinion on biological therapy.

[37]  N. Gallay,et al.  The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities , 2007, Stem cells.

[38]  D. Prockop Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  A. Nauta,et al.  Immunomodulatory properties of mesenchymal stromal cells. , 2007, Blood.

[40]  Ruth S. Waterman,et al.  Ovarian cancers overexpress the antimicrobial protein hCAP‐18 and its derivative LL‐37 increases ovarian cancer cell proliferation and invasion , 2007, International journal of cancer.

[41]  Frank P Barry,et al.  Mesenchymal stem cells avoid allogeneic rejection , 2005, Journal of Inflammation.

[42]  A. P. Robinson,et al.  Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses , 2008, Proceedings of the National Academy of Sciences.

[43]  F. Lanza,et al.  A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. , 2008, Cytotherapy.

[44]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[45]  M. Andreeff,et al.  Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. , 2005, Cancer research.

[46]  L. Cosmi,et al.  Toll‐Like Receptors 3 and 4 Are Expressed by Human Bone Marrow‐Derived Mesenchymal Stem Cells and Can Inhibit Their T‐Cell Modulatory Activity by Impairing Notch Signaling , 2008, Stem cells.

[47]  T. Golde,et al.  Notch 1 and TGF 1 cooperatively regulate Foxp 3 expression and the maintenance of peripheral regulatory T cells , 2008 .

[48]  T. Golde,et al.  Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. , 2008, Blood.

[49]  J J Padgett,et al.  A renewed sense of self. , 1994, Journal of psychosocial nursing and mental health services.

[50]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[51]  Kazuya Sato,et al.  Cell and gene therapy using mesenchymal stem cells (MSCs). , 2008, Journal of autoimmunity.

[52]  A. Caplan,et al.  The Dynamic in vivo Distribution of Bone Marrow-Derived Mesenchymal Stem Cells after Infusion , 2001, Cells Tissues Organs.

[53]  M. Liebergall,et al.  The Induction of APC with a Distinct Tolerogenic Phenotype via Contact-Dependent STAT3 Activation , 2009, PloS one.

[54]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[55]  Ruth S. Waterman,et al.  Toll‐Like Receptors on Human Mesenchymal Stem Cells Drive Their Migration and Immunomodulating Responses , 2008, Stem cells.

[56]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[57]  R. Romieu-Mourez,et al.  Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1 , 2009, The Journal of Immunology.

[58]  J. Pollard Trophic macrophages in development and disease , 2009, Nature Reviews Immunology.

[59]  D J Prockop,et al.  Donor variation in the growth properties and osteogenic potential of human marrow stromal cells , 1999, Journal of cellular biochemistry.

[60]  Sankar Ghosh,et al.  Recognition and signaling by toll-like receptors. , 2006, Annual review of cell and developmental biology.